Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Fig. 2

Percent change in hemoglobin level from baseline to end of cycle 4 (week 12). Values shown are for evaluable patients in study part B who received 10 mg/kg LY2787106 weekly (QW) without and with oral iron (cohorts B1 [n = 6] and B2 [n = 7], respectively). Only patients with a baseline and postbaseline result are included; for patients who did not reach week 12, their final assessment was used

Back to article page